Diltiazem Hydrochloride | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Diltiazem Hydrochloride
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Diltiazem Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

43 API Suppliers, 20 USDMF, 8 CEP/COS, 5 JDMF, 5 EU WC, 6 KDMF, 17 NDC API, 23 Listed Suppliers, $ API Reference Price

43 API Suppliers
20 USDMF
8 CEP/COS
5 JDMF
5 EU WC
6 KDMF
17 NDC API
23 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

353 FDF Dossiers, 222 FDA Orange Book, 18 Europe, 87 Canada, 7 South Africa, 19 Listed Dossiers

353 FDF Dossiers
222 FDA Orange Book
18 Europe
87 Canada
7 South Africa
19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 120MG, TABLET;ORAL - 30MG, TABLET;ORAL - 60MG, TABLET;ORAL - 90MG, CAPSULE, EXTENDED RELEASE;ORAL - 120MG, CAPSULE, EXTENDED RELEASE;ORAL - 180MG, CAPSULE, EXTENDED RELEASE;ORAL - 240MG, CAPSULE, EXTENDED RELEASE;ORAL - 300MG, CAPSULE, EXTENDED RELEASE;ORAL - 360MG, CAPSULE, EXTENDED RELEASE;ORAL - 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 180MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 120MG, CAPSULE, EXTENDED RELEASE;ORAL - 180MG, CAPSULE, EXTENDED RELEASE;ORAL - 240MG, CAPSULE, EXTENDED RELEASE;ORAL - 300MG, CAPSULE, EXTENDED RELEASE;ORAL - 360MG, CAPSULE, EXTENDED RELEASE;ORAL - 420MG, TABLET, EXTENDED RELEASE;ORAL - 120MG, TABLET, EXTENDED RELEASE;ORAL - 180MG, TABLET, EXTENDED RELEASE;ORAL - 240MG, TABLET, EXTENDED RELEASE;ORAL - 300MG, TABLET, EXTENDED RELEASE;ORAL - 360MG, TABLET, EXTENDED RELEASE;ORAL - 420MG

TABLET;ORAL - 120MG
TABLET;ORAL - 30MG
TABLET;ORAL - 60MG
TABLET;ORAL - 90MG
CAPSULE, EXTENDED RELEASE;ORAL - 120MG
CAPSULE, EXTENDED RELEASE;ORAL - 180MG
CAPSULE, EXTENDED RELEASE;ORAL - 240MG
CAPSULE, EXTENDED RELEASE;ORAL - 300MG
CAPSULE, EXTENDED RELEASE;ORAL - 360MG
CAPSULE, EXTENDED RELEASE;ORAL - 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 180MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 120MG
CAPSULE, EXTENDED RELEASE;ORAL - 180MG
CAPSULE, EXTENDED RELEASE;ORAL - 240MG
CAPSULE, EXTENDED RELEASE;ORAL - 300MG
CAPSULE, EXTENDED RELEASE;ORAL - 360MG
CAPSULE, EXTENDED RELEASE;ORAL - 420MG
TABLET, EXTENDED RELEASE;ORAL - 120MG
TABLET, EXTENDED RELEASE;ORAL - 180MG
TABLET, EXTENDED RELEASE;ORAL - 240MG
TABLET, EXTENDED RELEASE;ORAL - 300MG
TABLET, EXTENDED RELEASE;ORAL - 360MG
TABLET, EXTENDED RELEASE;ORAL - 420MG

RELATED EXCIPIENT COMPANIES

14 Evonik, 4 Rochem International Inc, 20 SPI Pharma, 2 Seqens, 9 DKSH, 8 Faran Shimi Pharmaceutical, 6 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 10 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 32 BASF, 22 Corel Pharma Chem, 5 DFE Pharma, 2 Finar, 11 Gangwal Chemicals, 13 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 31 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 19 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 9 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 33 Roquette, 14 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Valens Pharmachem, 3 Vasa Pharmachem, 3 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

98 Fillers, Diluents & Binders, 78 Coating Systems & Additives, 62 Controlled & Modified Release, 39 Solubilizers, 37 Thickeners and Stabilizers, 35 Direct Compression, 31 Taste Masking, 30 Granulation, 29 Film Formers & Plasticizers, 23 Disintegrants & Superdisintegrants, 22 Parenteral, 21 Lubricants & Glidants, 18 Chewable & Orodispersible Aids, 18 Co-Processed Excipients, 16 Topical, 11 Emulsifying Agents, 9 Empty Capsules, 7 Rheology Modifiers, 6 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 1 Soft Gelatin

98 Fillers, Diluents & Binders
78 Coating Systems & Additives
62 Controlled & Modified Release
39 Solubilizers
37 Thickeners and Stabilizers
35 Direct Compression
31 Taste Masking
30 Granulation
29 Film Formers & Plasticizers
23 Disintegrants & Superdisintegrants
22 Parenteral
21 Lubricants & Glidants
18 Chewable & Orodispersible Aids
18 Co-Processed Excipients
16 Topical
11 Emulsifying Agents
9 Empty Capsules
7 Rheology Modifiers
6 API Stability Enhancers
5 Coloring Agents
4 Vegetarian Capsules
4 Surfactant & Foaming Agents
1 Soft Gelatin

DIGITAL CONTENT

33 NEWS #PharmaBuzz

33 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 63 Finished Drug Prices, 1 Annual Reports

7 US Medicaid Prescriptions
63 Finished Drug Prices
1 Annual Reports

MARKET PLACE

13 APIs, 1 FDF Dossiers

13 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

25 Health Canada Patents

25 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 2 Others

3 EDQM
3 USP
2 Others

ANALYTICAL

2 Analytical Methods

2 Analytical Methods

$ API Ref.Price (USD/KG) : 94 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

25 All

01 14Valeant Canada LP

02 11Valeant Canada LP / Valeant Canada S.E.C.

filter Patent Reset all filters

25 All

01 102111085

02 102242224

03 52307547

filter Product Reset all filters

25 All

01 25Diltiazem Hydrochloride

filter Dosage Reset all filters

25 All

01 10Capsule

02 15Tablet

filter Exp Date Reset all filters

25 All

01 102012-06-25

02 102016-12-23

03 52020-05-04

Product Main Page

01

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 120 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 180 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 240 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 300 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Diltiazem Hydrochloride

Brand Name : TIAZAC

Patent Number : 2242224

Filing Date : 1996-12-23

Strength per Unit : 360 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2016-12-23

Date Granted : 2004-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 120 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 180 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 240 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 300 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

Valeant Canada LP

Diltiazem Hydrochloride

BioAsia

Not Confirmed

Valeant Canada LP

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Diltiazem Hydrochloride

Brand Name : TIAZAC XC

Patent Number : 2307547

Filing Date : 2000-05-04

Strength per Unit : 360 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-05-04

Date Granted : 2007-08-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!